

PRRT Dosimetry

1. U. Eberlein, M. Cremonesi, and M. Lassmann, "Individualized dosimetry for theranostics: Necessary, nice to have, or counterproductive?," *Journal of Nuclear Medicine*, vol. 58. Society of Nuclear Medicine Inc., pp. 975-1035, Sep. 01, 2017, doi: 10.2967/jnumed.116.186841.
2. M. G. Stabin, M. T. Madsen, and H. Zaidi, "Personalized dosimetry is a must for appropriate molecular radiotherapy," *Med. Phys.*, vol. 46, no. 11, pp. 4713–4716, Nov. 2019, doi: 10.1002/mp.13820.
3. L. Strigari et al., "The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 41, no. 10. Springer Berlin, pp. 1976–1988, 2014, doi: 10.1007/s00259-014-2824-5.

Personalized Dosimetry - Overview

1. A. S. Nelson, D. Mirando, A. Kruzer, and R. Niman, "Dosimetry for Targeted Molecular Radiotherapy Determination of Time-Integrated Activity Concentration " (white paper).
2. "Clinical utility of a 3D convolutional neural network kidney segmentation method for radionuclide dosimetry."
http://jnm.snmjournals.org/content/60/supplement_1/267
(accessed May 04, 2020).
3. L. Santoro et al., "Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate," *EJNMMI Res.*, vol. 8, no. 1, pp. 103–103, Nov. 2018, doi: 10.1186/s13550-018-0459-4

Dosimetry for Lu-177 Treatments

1. E. Ilan et al., "Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE," *J. Nucl. Med.*, vol. 56, no. 2, pp. 177–182, Feb. 2015, doi: 10.2967/jnumed.114.148437.
2. M. Del Prete et al., "Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 46, no. 3, pp. 728–742, Mar. 2019, doi: 10.1007/s00259-018-4209-7.
3. "Personalized therapy planning for 177Lu-DOTATATE using a kidney-driven dose optimization method."
http://jnm.snmjournals.org/content/60/supplement_1/270_short?rss=1&related-urls=yes&legid=jnumed;60/supplement_1/270
(accessed May 04, 2020).

Dosimetry for I-131 Treatments

1. G. D. Flux et al., "A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 37, no. 2, pp. 270–275, Feb. 2010, doi: 10.1007/s00259-009-1261-3.
2. R. A. Gregory et al., "Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy," *Phys. Med. Biol.*, vol. 64, p. 15, 2019, doi: 10.1088/1361-6560/ab5b6c.
3. G. Sgouros et al., "Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) software," *J. Nucl. Med.*, vol. 45, no. 8, pp. 1366–1372, Aug. 2004.

Dosimetry and Organ at Risk Toxicity

1. A. Sundlöv et al., "Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 44, no. 9, pp. 1480–1489, Aug. 2017, doi: 10.1007/s00259-017-3678-4.
2. R. Barone et al., "Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship," *J. Nucl. Med.*, vol. 46, no. 1 SUPPL., Jan. 2005.
3. M. Cremonesi et al., "Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 45, no. 13. Springer Berlin Heidelberg, pp. 2426–2441, Dec. 01, 2018, doi: 10.1007/s00259-018-4044-x.

Quantitative SPECT Reconstruction

1. S. M. B. Peters et al., "Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems," *EJNMMI Phys.*, vol. 7, no. 1, p. 9, Dec. 2020, doi: 10.1186/s40658-020-0278-3.
2. A. S. Nelson and C. M. Officer, "Quantitative SPECT / CT Reconstruction with SPECTRA TM Quant," 2019.
3. P. Ritt, H. Vija, J. Hornegger, and T. Kuwert, "Absolute quantification in SPECT," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 38, no. SUPPL. 1, 2011, doi: 10.1007/s00259-011-1770-8.